Al-Ola Abdallah, MD, a myeloma physician and associate professor director of plasma cell disorder program at the University of Kansas Medical Center.
Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid Tumors
Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.
PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert
Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL
Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts